Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Alaunos Therapeutics, Inc.ZIOP · Entity 8339 | Director | May 07, 2019 | May 08, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Alaunos Therapeutics, Inc.
Report date May 07, 2019 · Filed May 08, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 398,050 |
Reported balance
After 2019-05-07 transaction · row 1
1 source rowRow 1 · 2019-05-07 · Exercise / conversion · Acquired 15,000 · Balance 398,050 |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.70 · Expires 2019-05-13 | Direct | 0 |
Reported balance
After 2019-05-07 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-05-07 · Exercise / conversion · Disposed 15,000 · Balance 0 F1: Fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: Fully vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 07, 2019 Filed May 8, 2019 20:37 UTC | Alaunos Therapeutics, Inc. ZIOP · Entity 8339 | Exercise / conversionStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $0.70 | $0.00 |
DisclosureSEC source: 0001209191-19-028239 · doc4.xml · derivative · entry 2 CANNON JAMES ANTHONY · CIK 0001338533 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2019-05-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Fully vested. Read SEC document |
| May 07, 2019 Filed May 8, 2019 20:37 UTC | Alaunos Therapeutics, Inc. ZIOP · Entity 8339 | Exercise / conversionCommon Stock | 15,000 | $0.70 | $10,500.00 |
DisclosureSEC source: 0001209191-19-028239 · doc4.xml · nonDerivative · entry 1 CANNON JAMES ANTHONY · CIK 0001338533 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 398,050 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 31, 2018 Filed Jan 3, 2019 02:14 UTC | Alaunos Therapeutics, Inc. ZIOP · Entity 8339 | GrantStock Option (right to buy) · Derivative | 126,700 | $0.00 Strike: $1.87 | $0.00 |
DisclosureSEC source: 0001209191-19-000585 · doc4.xml · derivative · entry 2 CANNON JAMES ANTHONY · CIK 0001338533 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,700 Underlying: Common Stock · 126,700 shares Expires 2028-12-31 F2 · derivative.exercise_date: 126,700 options vest on 12/31/2019. Read SEC document |
| December 29, 2018 Filed Jan 3, 2019 02:14 UTC | Alaunos Therapeutics, Inc. ZIOP · Entity 8339 | Tax withholdingCommon Stock | 4,315 | $1.66 | $7,162.90 |
DisclosureSEC source: 0001209191-19-000585 · doc4.xml · nonDerivative · entry 1 CANNON JAMES ANTHONY · CIK 0001338533 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 383,050 F1 · shares: Represents shares withheld to satisfy withholding tax obligations upon the vesting of restricted stock grants. Read SEC document |
| December 30, 2017 Filed Jan 3, 2018 21:53 UTC | Alaunos Therapeutics, Inc. ZIOP · Entity 8339 | Tax withholdingCommon Stock | 4,301 | $4.14 | $17,806.14 |
DisclosureSEC source: 0001209191-18-000988 · doc4.xml · nonDerivative · entry 2 CANNON JAMES ANTHONY · CIK 0001338533 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 387,365 F2 · shares: Represents shares withheld to satisfy withholding tax obligations upon the vesting of restricted stock grants. Read SEC document |
| December 29, 2017 Filed Jan 3, 2018 21:53 UTC | Alaunos Therapeutics, Inc. ZIOP · Entity 8339 | GrantCommon Stock | 17,258 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-000988 · doc4.xml · nonDerivative · entry 1 CANNON JAMES ANTHONY · CIK 0001338533 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 391,666 F1 · shares: 17,258 shares vest on 12/29/2018. Read SEC document |
| December 12, 2017 Filed Dec 13, 2017 21:38 UTC | Alaunos Therapeutics, Inc. ZIOP · Entity 8339 | Exercise / conversionStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $2.73 | $0.00 |
DisclosureSEC source: 0001209191-17-065442 · doc4.xml · derivative · entry 3 CANNON JAMES ANTHONY · CIK 0001338533 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2017-12-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 6,667 shares vested on each of 12/12/08 and 12/12/09; 6,666 shares vested on 12/12/10. Read SEC document |
| December 12, 2017 Filed Dec 13, 2017 21:38 UTC | Alaunos Therapeutics, Inc. ZIOP · Entity 8339 | Tax withholdingCommon Stock | 13,094 | $4.17 | $54,601.98 |
DisclosureSEC source: 0001209191-17-065442 · doc4.xml · nonDerivative · entry 2 CANNON JAMES ANTHONY · CIK 0001338533 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 374,408 F1 · shares: Represents shares withheld to pay exercise price. Read SEC document |
| December 12, 2017 Filed Dec 13, 2017 21:38 UTC | Alaunos Therapeutics, Inc. ZIOP · Entity 8339 | Exercise / conversionCommon Stock | 20,000 | $2.73 | $54,600.00 |
DisclosureSEC source: 0001209191-17-065442 · doc4.xml · nonDerivative · entry 1 CANNON JAMES ANTHONY · CIK 0001338533 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 387,502 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 12, 2017 Filed Jun 14, 2017 20:31 UTC | Alaunos Therapeutics, Inc. ZIOP · Entity 8339 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $4.85 | $0.00 |
DisclosureSEC source: 0001209191-17-039836 · doc4.xml · derivative · entry 2 CANNON JAMES ANTHONY · CIK 0001338533 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2017-06-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 5,000 shares vested and became exercisable on each of 6/18/08, 6/18/09 and 6/18/10. Read SEC document |
| June 12, 2017 Filed Jun 14, 2017 20:31 UTC | Alaunos Therapeutics, Inc. ZIOP · Entity 8339 | Exercise / conversionCommon Stock | 15,000 | $4.85 | $72,750.00 |
DisclosureSEC source: 0001209191-17-039836 · doc4.xml · nonDerivative · entry 1 CANNON JAMES ANTHONY · CIK 0001338533 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 367,502 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 31, 2016 Filed Jan 4, 2017 21:38 UTC | Alaunos Therapeutics, Inc. ZIOP · Entity 8339 | Tax withholdingCommon Stock | 6,665 | $5.35 | $35,657.75 |
DisclosureSEC source: 0001209191-17-000976 · doc4.xml · nonDerivative · entry 2 CANNON JAMES ANTHONY · CIK 0001338533 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 352,502 F2 · shares: Represents shares withheld to satisfy withholding tax obligations upon the vesting of restricted stock grants. Read SEC document |
| December 30, 2016 Filed Jan 4, 2017 21:38 UTC | Alaunos Therapeutics, Inc. ZIOP · Entity 8339 | GrantCommon Stock | 17,204 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-000976 · doc4.xml · nonDerivative · entry 1 CANNON JAMES ANTHONY · CIK 0001338533 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 359,167 F1 · shares: 17,204 shares vest on 12/30/2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.